Yueh-Chien Lin

Dr. Yueh-Chien Lin

Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
YLYu-Hsuan Lin
Yu-Hsuan Lin
YLYueh-Chien Lin
Yueh-Chien Lin
Chien-Chin ChenChien-Chin Chen
Chien-Chin Chen
Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer.

12 November 2019 in Aging Cell
Verified
Journal Article
Open access
PDF file
WCWei‐Min Chen
Wei‐Min Chen
JCJui-Chung Chiang
Jui-Chung Chiang
YLYueh-Chien Lin
Yueh-Chien Lin
YLYu‐Nung Lin
Yu‐Nung Lin
PCPei‐Yun Chuang
Pei‐Yun Chuang
HLHsinyu Lee
Hsinyu Lee
Hutchinson–Gilford progeria syndrome (HGPS) is a rare laminopathy that produces a mutant form of prelamin A, known as Progerin, resulting in premature aging. HGPS cells show morphological abnormalities of the nuclear membrane, reduced cell proliferation rates, accumulation of reactive oxygen species (ROS), and expression of senescence markers. Lysophosphatidic acid (LPA) is a growth factor‐like lipid mediator that regulates various physiological functions via activating multiple LPA G protein‐coupled receptors. Here, we study the roles of LPA and LPA receptors in premature aging. We report that the protein level of LPA3 was highly downregulated through internalization and the lysosomal degradation pathway in Progerin‐transfected HEK293 cells. By treating Progerin HEK293 cells with an LPA3 agonist (OMPT, 1‐Oleoyl‐2‐O‐methyl‐rac‐glycerophosphothionate) and performing shRNA knockdown of the Lpa3r transcript in these cells, we showed that LPA3 activation increased expression levels of antioxidant enzymes, consequently inhibiting ROS accumulation and ameliorating cell senescence. LPA3 was shown to be downregulated in HGPS patient fibroblasts through the lysosomal pathway, and it was shown to be crucial for ameliorating ROS accumulation and cell senescence in fibroblasts. Moreover, in a zebrafish model, LPA3 deficiency was sufficient to cause premature aging phenotypes in multiple organs, as well as a shorter lifespan. Taken together, these findings identify the decline of LPA3 as a key contributor to the premature aging phenotypes of HGPS cells and zebrafish.

1 March 2014 in Cellular Signalling
Verified
Journal Article
Closed access
YHYuan-Li Huang
Yuan-Li Huang
CCChi-Lun Chang
Chi-Lun Chang
CTChih-Hsin Tang
Chih-Hsin Tang
YLYueh-Chien Lin
Yueh-Chien Lin
TJTsai-Kai Ju
Tsai-Kai Ju
HLHsinyu Lee
Hsinyu Lee

31 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
PWPei-Yi Wu
Pei-Yi Wu
YLYueh-Chien Lin
Yueh-Chien Lin
YHYuan-Li Huang
Yuan-Li Huang
WCWei-Min Chen
Wei-Min Chen
Chien-Chin ChenChien-Chin Chen
Chien-Chin Chen
HLHsinyu Lee
Hsinyu Lee
Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA–VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa.

1 November 2013 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CLChu-Cheng Lin
Chu-Cheng Lin
CLChuan-En Lin
Chuan-En Lin
YLYueh-Chien Lin
Yueh-Chien Lin
TJTsai-Kai Ju
Tsai-Kai Ju
YHYuan-Li Huang
Yuan-Li Huang
HLHsinyu Lee
Hsinyu Lee

12 October 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
YHYuan-Li Huang
Yuan-Li Huang
YLYueh-Chien Lin
Yueh-Chien Lin
CLChu-Cheng Lin
Chu-Cheng Lin
WCWei-Min Chen
Wei-Min Chen
BCBenjamin P.C. Chen
Benjamin P.C. Chen
HLHsinyu Lee
Hsinyu Lee
Background/Aims: Hyperglycemia has been shown to increase the incidence and metastasis in various types of cancers. However, the correlation between hyperglycemia and lymphatic metastasis in prostate cancer (PCa) remains unclear. Our previous study demonstrated that lysophosphatidic acid (LPA) enhances vascular endothelial growth factor-C (VEGF-C) expression, a lymphangiogenic factor, through activating it receptors LPA1/3 in prostate cancer (PCa) cells. Moreover, hyperglycemia up-regulates autotaxin (ATX) expression, a LPA-generating enzyme. Therefore, we propose that high glucose promotes VEGF-C expression through LPA signaling in PCa cells. Methods: Pharmacological inhibitors and siRNAs were utilized to investigate the molecular mechanism of high glucose-induced VEGF-C expression. Real-time PCR and Western blot were used to determine the mRNA and protein expressions, respectively. Cellular bioenergetics analysis was performed to determine the glycolysis levels. Results: We demonstrated that the expressions of VEGF-C, ATX, and calreticulin were increased upon high glucose treatments in PC-3 cells. Moreover, high glucose-induced VEGF-C expression was mediated through the LPA1/3, PLC, Akt, ROS and LEDGF-dependent pathways. Additionally, high glucose enhanced the aerobic glycolysis via LPA1/3. Conclusion: These results indicated that hyperglycemia leads to LPA synthesis, and subsequent promoting pathological consequence of PCa. These novel findings could potentially provide new strategies for PCa treatments.